Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution.
A simple, sensitive and specific RP-HPLC method was developed for the quantification of related impurities of albuterol sulfate (AS) and ipratropium bromide (IB) in liquid pharmaceutical dosage form. The chromatographic separation employs gradient elution using an inertsil C8-3, 250mmx4.6mm, 5mum columns. Mobile phase consisting of solvent A (solution containing 2.5g of potassium dihydrogen phosphate and 2.87g of heptane-1-sulfonic acid sodium salt per liter of water, adjusted to pH 4 with orthophosphoric acid) and solvent B (acetonitrile) delivered at a flow rate of 1.0mlmin(-1). The analytes were detected and quantified at 210nm using photodiode array (PDA) detector. The method was validated as per ICH guidelines, demonstrating to be accurate and precise (repeatability and intermediate precision level) within the corresponding linear range of known impurities of AS and IB. The specificity of the method was investigated under different stress conditions including hydrolytic, oxidative, photolytic and thermal as recommended by ICH guidelines. Relevant degradation was found to take place under hydrolytic and oxidative conditions. Robustness against small modification in pH, column oven temperature, flow rate and percentage of the mobile phase composition was ascertained. Lower limit of quantification and detection were also determined. The peak purity indices (purity angle<purity threshold) obtained with the aid of PDA detection and satisfactory resolution between related impurities established the specificity of the determination. All these results provide the stability indicating capability of the method.
Kasawar
Gajanan B
GB
Post Graduate and Research Centre, Dr. Rafiq Zakaria Campus, Maulana Azad College, Rouza Bagh, Aurangabad, Pin code: 431001, India. gajukas2002@yahoo.co.in
Farooqui
Mazahar
M
D000281:Administration, Intranasal; D000420:Albuterol / Q000008:administration & dosage / Q000032:analysis*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000032:analysis*; D002021:Buffers; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid / Q000592:standards; D056148:Chromatography, Reverse-Phase / Q000592:standards; D004340:Drug Contamination; D004355:Drug Stability; D017408:Guidelines as Topic; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D009241:Ipratropium / Q000008:administration & dosage / Q000032:analysis*; D007700:Kinetics; D010084:Oxidation-Reduction; D019999:Pharmaceutical Solutions; D010782:Photolysis; D015203:Reproducibility of Results; D012997:Solvents / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000592:standards; D013696:Temperature
D001993:Bronchodilator Agents; D002021:Buffers; D019999:Pharmaceutical Solutions; D012997:Solvents; D009241:Ipratropium; D000420:Albuterol